Compare Bristol-Myers Squibb Co (BMY) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while YieldMax MSTR Option Income Strategy ETF trades at $13.38. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BMY | MSTY | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $114.30 |
52-Week Low | $42.60 | $11.55 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MSTY trades at $12.57, down 2.03% with bearish technical signals from moving averages. The ETF maintains aggressive weekly dividend distributions, though recent coverage highlights concerns about return of capital and NAV erosion. Technical indicators show RSI in neutral territory while moving averages signal continued downward pressure.
The outlook remains challenging with structural risks to the covered-call strategy capping upside potential while exposing investors to full downside. Recent analyst commentary emphasizes unsustainable yield dynamics and dependence on Bitcoin volatility. Investment requires careful consideration of distribution sustainability versus capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
